SBRA vs VTR: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of September 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: SBRA is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. SBRA and VTR share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined SBRA and VTR exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Sabra Health Care REIT is a self-managed real estate investment trust that owns and invests in healthcare property, including skilled nursing and transitional care facilities, managed senior housing communities, behavioral health, and specialty hospitals, spread across the United States and Canada. Its portfolio mixes triple-net leases (where operators pay Sabra fixed rent) with managed senior housing under RIDEA-style structures that give Sabra direct exposure to the operating income of those communities, so a chunk of its results moves with occupancy and rate trends in senior living.

Full SBRA guide

Ventas, Inc. is an S&P 500 healthcare real estate investment trust that owns roughly 1,400 properties across North America and the United Kingdom, spanning senior housing communities, outpatient medical buildings, and research and lab (life science) assets. Its defining shift has been toward its senior housing operating portfolio (SHOP), which now accounts for more than half of net operating income and gives Ventas direct exposure to occupancy, rate, and margin trends rather than just fixed lease income. The company owns over 850 senior housing communities, and management has leaned hard into buying them, raising 2026 investment guidance to about $3 billion because acquiring communities has looked more attractive than building.

Full VTR guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• SBRA drivers: Senior housing operating recovery; Investment pipeline and acquisitions.
• VTR drivers: Senior housing (SHOP) demographic tailwind; Capital deployment into acquisitions.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Sabra depends heavily on the financial health of its tenant operators, and skilled nursing operators in particular run on thin margins tied to Medicare and Medicaid reimbursement, so rate changes or operator distress can pressure rent collection. For VTR, as an operating (SHOP-heavy) REIT, Ventas carries more earnings variability than a pure net-lease landlord because occupancy, labor costs, and rate growth flow straight to NOI.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick SBRA if you believe its drivers more; VTR if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the SBRA and VTR guides.

SBRA. Sabra reported Q1 2026 revenue of about $222 million and normalized AFFO of roughly $0.39 per share, and management raised full-year 2026 guidance to call for mid-to-high single digit FFO and AFFO per share growth over 2025. On a REIT-appropriate basis the shares trade around 13 times forward FFO, which is a discount to larger senior-housing-focused peers. The quarterly dividend of about $0.30 represents a payout near 77% of normalized AFFO, leaving some cushion.

VTR. VTR trades around $96 with a market cap near $47 billion, making it the second-largest healthcare REIT behind Welltower. At roughly a mid-20s price-to-FFO multiple, the market is paying up for a fifth consecutive year of double-digit senior housing NOI growth. The dividend yield is modest for a REIT at about 2.1%, reflecting both the growth premium and a payout that management has been rebuilding since the pandemic.

Headline figures (approximate, July 2026): SBRA shows market cap ~$5.0B, revenue (ttm) ~$880M, normalized ffo/share (2026 guide) ~$1.53-$1.55, normalized affo/share (2026 guide) ~$1.59-$1.61; VTR shows revenue (ttm) ~$5.7B, q1 2026 revenue ~$1.66B, normalized ffo/share (q1 2026) ~$0.94, 2026 ffo/share guidance ~$3.82-$3.89.

SBRA and VTR are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined SBRA and VTR exposure against your real portfolio. It is not an investment adviser.